TrialPath
Type 1 diabetes · Miami

Type 1 diabetes clinical trials in Miami

20 recruiting type 1 diabetes studies within range of Miami. Click any trial for full eligibility criteria and contact info.

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

Recruiting

This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once every 14 days over 26 weeks with an additional 6-month follow-up period.

PhasePhase 2
TypeInterventional
Age8 Years – 45 Years
WhereSan Francisco, California, United States + 14 more
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
▾Tap for details
Apply

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

NCT02846571 · Diabetes
Recruiting

The intervention in this trial is intraocular islet transplantation. A single dose of 1000 - 3000 Islet Equivalents (IEQ)/kg recipient body weight (BW) will be infused into the anterior chamber of the eye through a self-sealing incision in the peripheral cornea. The procedure is projected to take approximately 20-30 minutes. Transplant recipients in this study will receive localized maintenance immunosuppression via topical application of eye-drops.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 75 Years
WhereMiami, Florida, United States + 1 more
SponsorMidhat H. Abdulreda
▾Tap for details
Apply

A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

NCT04786262 · Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Recruiting

This study will evaluate the safety, tolerability and efficacy of VX-880 infusion and VX-017 infusion in participants with type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.

PhasePhase 3
TypeInterventional
Age18 Years – 65 Years
WhereDuarte, California, United States + 28 more
SponsorVertex Pharmaceuticals Incorporated
▾Tap for details
Apply

Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss

Recruiting

This is a single-center, prospective, open label study in islet transplant recipients following islet graft loss.

Phase—
TypeObservational
Age18 Years – 75 Years
WhereMiami, Florida, United States
SponsorRodolfo Alejandro
▾Tap for details

A Study of GNTI-122 in Adults Recently Diagnosed With T1D

Recruiting

This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnosed T1D. After assessment of eligibility, participants who qualify for the study will be enrolled sequentially in 1 of 3 cohorts. Cohort 1 participants (n=3) receive a low dose of GNTI-122 . Cohort 2 participants (n=3) receive a high dose of GNTI-122. Cohort 3 participants (n=10) receive a high dose of GNTI-122 in combination with rapamycin. Participants are followed for 78 weeks after the administration of GNTI-122 during which safety and efficacy assessments are made, including vital signs, ECG, physical exam, clinical labs, and monitoring of adverse events and concomitant medications. Disease markers (e.g., MMTT-stimulated C-peptide, HbA1c) and pharmacodynamic activity (e.g., lymphocyte subsets and phenotypes, effector T cell responses to islet antigens ex vivo, T1D autoantibodies) will be monitored serially throughout the study. The study will include sentinel dosing and a Safety Review Committee to ensure participant safety. Visit https://www.polarisstudy.com to learn more!

PhasePhase 1
TypeInterventional
Age18 Years – 55 Years
WhereDuarte, California, United States + 9 more
SponsorGentiBio, Inc
▾Tap for details
Apply

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Recruiting

This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.

PhaseNA
TypeInterventional
Age18 Years – 70 Years
WhereMiami, Florida, United States
SponsorRodolfo Alejandro
▾Tap for details

A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

NCT07803744 · Diabetes Mellitus, Type 1, Overweight, Obesity
Recruiting

The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity. Participation in this study will last about 8 weeks, including screening and follow-up.

PhasePhase 1
TypeInterventional
Age18 Years – 70 Years
WhereMiami, Florida, United States
SponsorEli Lilly and Company
▾Tap for details
Apply

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07564414 · Obesity, Type 2 Diabetes
Recruiting

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

PhasePhase 3
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 302 more
SponsorNovo Nordisk A/S
▾Tap for details
Apply

Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency

NCT07385547 · Type II Diabetes Mellitus
Recruiting

This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist. Approximately 40 adult participants will be enrolled across four groups: normal renal function, moderate renal impairment, severe renal impairment without dialysis, and severe renal impairment with dialysis. Each participant will receive a single subcutaneous dose of GL0034. Blood samples will be collected for PK analysis. Secondary objectives include assessing safety and tolerability. The study will help determine whether renal impairment affects GL0034 exposure and inform dosing recommendations for patients with compromised renal function.

PhasePhase 1
TypeInterventional
Age18 Years – 80 Years
WhereMiami, Florida, United States + 2 more
SponsorSun Pharmaceutical Industries Limited
▾Tap for details
Apply

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

NCT07061574 · Type 1 Diabetes, New Onset
Recruiting

This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.

PhasePhase 1 / Phase 2
TypeInterventional
Age9 Years – 20 Years
WhereLos Angeles, California, United States + 10 more
SponsorCity of Hope Medical Center
▾Tap for details
Apply

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335 · Type 2 Diabetes, Cardiovascular Risk
Recruiting

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.

PhasePhase 3
TypeInterventional
Age45 Years
WhereBirmingham, Alabama, United States + 329 more
SponsorNovo Nordisk A/S
▾Tap for details
Apply

A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

NCT07881887 · Obesity, Overweight, Diabetes Mellitus, Type 2
Recruiting

The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.

PhasePhase 1
TypeInterventional
Age18 Years – 65 Years
WhereRogers, Arkansas, United States + 14 more
SponsorEli Lilly and Company
▾Tap for details
Apply

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

NCT05626712 · Type 1 Diabetes, Diabetes Mellitus, Type 1
Recruiting

The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 35 Years
WhereMiami, Florida, United States
SponsorCreative Medical Technology Holdings Inc
▾Tap for details
Apply

Long Term Follow up of Recipients of Functional Islet Allografts

Recruiting

Since its inception, the Diabetes Research Institute (DRI) has made significant contributions to the field of diabetes, pioneering many of the techniques used in diabetes centers around the world. Through several clinical trials, DRI has demonstrated that diabetes can be successfully reversed as a result of islet cell transplant. Over the years the following protocols in islet cell transplantation have been initiated: 2000/0329; 2000/0196; 2004/0205; 2000/024; 2006/0200; 2006/0508; 2006/0210. All of the studies listed above will be source of study subjects for this study. Approximately 30 subjects are expected to be enrolled and followed in this trial. After islet-cell transplantation in the parent studies, each subject receives maintenance immunosuppressive medications. The purpose of this protocol is to collect additional follow-up for safety and efficacy from subjects with graft function after their completion in their parent study. It is expected that most subjects will retain measurable islet function and, in the islet-alone studies, continue to receive immunosuppressive medications at the time of completing their parent study.

Phase—
TypeObservational
Age18 Years – 65 Years
WhereMiami, Florida, United States
SponsorRodolfo Alejandro
▾Tap for details
Apply

Registry for Stage 2 Type 1 Diabetes

NCT06481904 · Type 1 Diabetes
Recruiting

Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general information on patients with stage 2 T1D and further information on the long-term effects of TZIELD® in patients with Stage 2 T1D, treated as per standard of care.

Phase—
TypeObservational
AgeAny
WhereLos Angeles, California, United States + 36 more
SponsorSanofi
▾Tap for details
Apply

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531 · Type 1 Diabetes
Recruiting

This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).

PhasePhase 2
TypeInterventional
Age5 Years – 40 Years
WhereSan Francisco, California, United States + 67 more
SponsorSAb Biotherapeutics, Inc.
▾Tap for details
Apply

A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes

NCT07568678 · Type 2 Diabetes
Recruiting

The study is to assess the safety, pharmacokinetics, and pharmacodynamic profile of HMS1005 in patient with diabetes

PhasePhase 1
TypeInterventional
Age18 Years – 65 Years
WhereMiami, Florida, United States
SponsorHua Medicine Limited
▾Tap for details
Apply

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

NCT06783309 · Type 1 Diabetes Mellitus, T1D, T1DM
Recruiting

This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (275 days).

PhasePhase 1 / Phase 2
TypeInterventional
Age12 Years – 35 Years
WhereTucson, Arizona, United States + 44 more
SponsorCOUR Pharmaceutical Development Company, Inc.
▾Tap for details
Apply

Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

NCT07676565 · Type 1 Diabetes
Recruiting

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

Phase—
TypeObservational
Age18 Years
WhereNewport Beach, California, United States + 16 more
SponsorIndiana University
▾Tap for details
Apply

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907 · Weight Management
Recruiting

The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM). The primary objectives of this study are: * To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571. * To evaluate the effect of concomitant food intake and (if conducted) a representative acid-reducing agent (proton pump inhibitor (PPI), omeprazole) on the PK of GS-4571. * To evaluate the safety and tolerability of single and multiple ascending oral doses of GS-4571.

PhasePhase 1
TypeInterventional
Age18 Years – 65 Years
WhereMiami, Florida, United States + 2 more
SponsorGilead Sciences
▾Tap for details
Apply